Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Endocrinology | Family Medicine
 Disease Category: Diabetes Mellitus Types I and II
Location: United States, TX

Trial Information

LEADER, Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results. A long-term, multi-center, international, randomised double-blind, placebo-controlled trial to determine liraglutide effects on cardiovascular events

IRB Number: 010-184

This is a study evaluating a drug currently approved by the FDA. The drug liraglutide will be tested on people with a cardiovascular past and will assess cardiovascular outcomes, weight, and glycemic control and other various factors.

Inclusion Criteria:

  • Men or women- 2 diabetes
  • 50 years or older
  • Have previous cardiovascular problems including cerebrovascular, cardiovascular or peripheral vascular disease, chronic renal failure, chronic heart failure, heart attack, stroke, or stenosis
  • Are naïve to diabetes drugs or currently are on a stable dose of orals or long acting insulin such as; lantus, detemir, NPH
  • HgA1c of 7.0 or greater

Exclusion Criteria:

  • Cancer in the last 5 years
  • Currently taking short-acting insulin

Priscilla Hollander, MD
Baylor Research Institute
3600 Gaston Ave, Wadley #656
Dallas, TX 75246
Phone: 214-818-7155

View Map

Research Center Information: Baylor Research Institute

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.